Hikma Pharmaceuticals, a leading multinational pharmaceutical group with operations across the Middle East and North Africa (Mena), Europe and the United States, has posted a nine per cent increase in revenue, with returns of $1.4 billion last year.

The increase was driven by significant growth in Hikma’s global Injectables business, which achieved a 33 per cent rise in revenues, said a statement.

In addition, Hikma acquired the assets of Bedford and Ben Venue Laboratories from Boehringer Ingelheim, ensuring sustainable long-term development of its global Injectables business, it said.

The revenues from Hikma’s global branded business grew one per cent in line with the strong performance in 2013. Additionally, revenues from Hikma’s global Generics business reflected strong underlying growth from the re-launch of legacy products and the expected decline in sales from specific market opportunities.

Across all businesses and markets, Hikma launched a total of 75 products and received 263 product approvals last year.

Mazen Darwazeh, vice chairman, president and chief executive officer of Mena and Emerging Markets at Hikma, said: “Hikma’s excellent performance in 2014 is mainly due to the positive growth in our global Injectables business, which we expect to continue to deliver stable revenues in 2015. This demonstrates our product portfolio’s appeal, particularly in the United States, in addition to the dedicated efforts of our sales team and the adaptability of our manufacturing capacities.

“In the Mena region, we succeeded in expanding our Branded business through our continued focus on strategic, higher value offerings and new product launches, and we are confident that we will achieve increased profitability in 2015. Our Generics business continues to be a major contributor to Hikma, and our planned future investments will help to sustain this performance.”
     
Meanwhile, Hikma inaugurated its Oncology API (Active Pharmaceuticals Ingredients) Chemicals manufacturing plant in Jordan last year, thus completing the production cycle for cancer medicines and offering patients worldwide treatment options at a lower cost. - TradeArabia News Service